The global liquid biopsy market was valued at USD 9.63 billion in 2024 and is expected to grow from USD 11.66 billion in 2025 to USD 58.64 billion by 2032, registering a CAGR of 25.9% during the forecast period. In 2024, North America led the global liquid biopsy market, accounting for a 54.43% share.

The liquid biopsy market is emerging as a transformative tool in cancer diagnostics and monitoring. It enables the detection of tumor-derived materials such as circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) through a non-invasive blood draw. This technology offers significant advantages over traditional tissue biopsies, including real-time disease tracking, early detection, and treatment response assessment. Growing demand for personalized medicine, increasing cancer prevalence, and advancements in next-generation sequencing technologies are key factors driving the expansion of the global liquid biopsy market.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506**

Liquid Biopsy Market Overview & Key Metrics

Market Size & Forecast

• The global liquid biopsy market was valued at USD 9.63 billion in 2024, with growth expected to reach USD 11.66 billion in 2025.
• By 2032, the market is projected to surge to USD 58.64 billion, registering a strong CAGR of 25.9% from 2025 to 2032.
• This growth is fueled by increasing demand for non-invasive cancer diagnostics, early screening solutions, and advancements in molecular testing technologies.

Market Share

• By Region:
• North America led the global liquid biopsy market in 2024 with a 43% share, supported by:
  • Rapid adoption of precision oncology tools.
  • Robust innovation pipelines from major diagnostic companies.
  • Favorable reimbursement policies across the U.S. and Canada.
• By Product:
• Kits & reagents held the largest market share in 2024, driven by:
  • Frequent product approvals for circulating tumor DNA (ctDNA) and non-invasive prenatal testing (NIPT).
  • Companies like Illumina, Guardant Health, and Foundation Medicine expanding their assay portfolios to offer high-sensitivity, fast-turnaround solutions.

Key Country Highlights

• United States:
  • Leads the market with significant R&D investments and widespread adoption of liquid biopsy technologies.
  • The approval of assays like Guardant360 CDx for non-small cell lung cancer (NSCLC) reflects FDA support for advanced oncology diagnostics.
  • Post-COVID trends have driven increased use of at-home cancer testing solutions.
• India:
  • Rising cancer cases—from 1.39 million in 2020 to 1.46 million in 2022—are creating a stronger need for early detection.
  • Government initiatives and data from ICMR are supporting broader adoption of NIPT and oncology screening, especially in urban healthcare settings.
• China:
  • Market growth is propelled by increased investment in genetic testing infrastructure and a rapidly aging population.
  • Expansion of molecular diagnostic laboratories and local biotech innovation is improving accessibility for oncology and prenatal liquid biopsy tests.
• Europe:
  • Growth is supported by strong regulatory frameworks and government-backed cancer screening programs.
  • The U.K.’s NHS has launched early detection initiatives using liquid biopsy, while countries like Germany and France are expanding national NIPT coverage.
  • Companies such as Dxcover Ltd. are receiving public funding to develop next-generation diagnostic platforms.